EUVIMEDEUVIMED entdecken
Crossref

Comparative evaluation of olanzapine and risperidone in schizophrenia patients using the positive and negative syndrome scale

Shruti Vihang Brahmbhatt

Bioinformation · 31.07.2026 · 22 (7) · 4187-4192

DOI: 10.6026/973206300224187 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioinformation, online erschienen am 31.07.2026. Verfasst von Shruti Vihang Brahmbhatt.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Schizophrenia is a chronic psychiatric disorder associated with substantial disability, persistent symptom burden and premature mortality. Therefore, it is of interest to compare the 12-week effectiveness and safety of olanzapine and risperidone monotherapy in 40 newly diagnosed patients with schizophrenia-spectrum disorders in a rural Indian tertiary-care setting. Both groups showed significant clinical improvement, but olanzapine showed greater reduction in PANSS positive, negative and total scores by month three, with total PANSS scores of 62.1 ± 8.7 versus 69.3 ± 9.4 in the risperidone group. Olanzapine was associated with greater mean weight gain and more weight-related adverse events, whereas risperidone was associated with a higher frequency of extrapyramidal symptoms. Thus, data shows the importance of antipsychotic selection based on expected efficacy, metabolic risk, and neurological tolerability and structured follow-up monitoring.

Zitieren

APA

Brahmbhatt, S. V. (2026). Comparative evaluation of olanzapine and risperidone in schizophrenia patients using the positive and negative syndrome scale. Bioinformation, 22(7), 4187-4192. https://doi.org/10.6026/973206300224187

Vancouver

Brahmbhatt SV. Comparative evaluation of olanzapine and risperidone in schizophrenia patients using the positive and negative syndrome scale. Bioinformation. 2026;22(7):4187-4192. doi:10.6026/973206300224187

BibTeX
@article{Brahmbhatt2026,
  author = {Brahmbhatt, Shruti Vihang},
  title = {Comparative evaluation of olanzapine and risperidone in schizophrenia patients using the positive and negative syndrome scale},
  journal = {Bioinformation},
  year = {2026},
  volume = {22},
  number = {7},
  pages = {4187--4192},
  doi = {10.6026/973206300224187}
}
Kostenlos starten →